An interventional study of transcutaneous vagus nerve stimulation and Monitoring in Post-COVID-19 Syndrome, sponsored by University Hospital Tuebingen. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.
Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 12th largest by planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2024, is one of 20 with no phase, reaches primary completion later than 11 of the 16 other live ones, and was the 33rd registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18+
Eggensberger OHG · Sites in Germany
Ages 18+
Max-Planck-Institute of Psychiatry · Sites in Germany
Ages 18–65
Schön Klinik Berchtesgadener Land · Sites in Germany
Ages 18+
Hellenic Institute for the Study of Sepsis · Sites in Germany, Greece, Italy and 1 more country
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3
First in 2018; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 108 across the 28 interventional studies, 130 across the 13 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 41 have an industry lead sponsor. The 10 most frequent:
University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
University Hospital Tuebingen has 2 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Post-Acute COVID-19 Syndrome with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197138Max-Planck-Institute of PsychiatryIMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition | 2027-01 |
| NCT07110714Eggensberger OHGEffects of Kneipp Hydrotherapy in Post-COVID-19 Patients | 2027-01-31 |
| NCT07013903Schön Klinik Berchtesgadener LandEffects of Hydrotherapy During Post-COVID-19 Rehabilitation | 2027-01-31 |
| NCT06510985University Hospital TuebingenTranscutaneous Vagus Nerve Stimulation (tVNS) for Improved Recovery After Exertion. | 2027-05 |
| NCT05638724Technical University of MunichMunich Long COVID Registry for Children, Adolescents, and Adults | 2027-07-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Widespread infection with SARS-CoV-2 has resulted in millions of people having Post-COVID. Post-COVID is a complex, non-monolithic disease with diverse clinical manifestations. Symptoms range from fatigue, brain fog, muscle aches and shortness of breath, affecting multiple organ systems simultaneously. To directly address this multi-organ component of Post-COVID, innovative treatment methods are urgently needed. One potential treatment that we will investigate in our study, is the intervention via the vagus nerve, as the cranial nerve plays a central role in communication between the body and the brain and influences targeted behavior. This innovative approach is based on our clinically relevant findings regarding the effects where acute tVNS increased the level of effort (Neuser et al., 2020; Ferstl et al., 2021), specifically targeting a key symptom of Post-COVID. In the proposed study, the investigators aim to investigate the effectiveness of transcutaneous vagus nerve stimulation (tVNS) as a non-invasive, self-administered treatment for Post-COVID symptoms at home. To evaluate the clinically relevant effects of repeated taVNS application (high-intensity stimulation), the investigators will employ a randomized cross-over design to investigate stimulation-induced changes in fatigue, depression and motivation to work for reward compared to low-intensity stimulation and to a control group.
The proposed study aims to advance the understanding of Post-COVID treatment using a randomized cross-over design to evaluate the taVNS-induced changes over 12 weeks. A hundred twenty patients diagnosed with Long/Post-COVID are randomly assigned to one of three groups related to the two arms of the study ("Monitoring with low/high-intensity stimulation" vs. Monitoring without stimulation"). In the treatment group, forty patients will start with high-intensity taVNS for 6 weeks, then switch to low-intensity stimulation for an additional 6 weeks. Another 40 patients begin with low-intensity stimulation for 6 weeks, followed by high-intensity taVNS stimulation. The control group ("Monitoring without stimulation") is able to receive taVNS after participation in the study.
The treatment group and the control group will participate in the same monitoring procedures. All participants will attend an initial laboratory session to complete several baseline assessments, including questionnaires, measuring energy expenditure via indirect calorimetry and completing a body silhouette task. Blood samples are taken at every session to evaluate changes in metabolic and inflammatory markers. To assess the motivation to work for rewards, the investigators employ an effort-based-cost-benefit paradigm (Effort Allocation Task). All these lab assessments will be repeated after 6 and 12 weeks to evaluate stimulation-induces changes in primary and secondary outcomes. In addition, all participants are given a cardio bracelet to monitor physiological parameters (e.g. heart rate, heart rate variability, breathing, skin conductance, step counts) over the study period. Over the 12 weeks, the treatment group will self-administer taVNS for four hours daily in a targeted manner, anticipating forthcoming exertion and stimulating in anticipation of an effortful event to enhance the patients' motivational drive and recovery. Another essential part of the study is the monitoring over the 12 weeks. All participants will complete daily ecological momentary assessments via smartphone to monitor their mental states. In addition, participants will perform once a day one of two discounting games (effort or temporal discounting task) to investigate changes in their decision behavior over time. The effort discounting task is essential to assess the motivation of post-COVID patients to pursue subjectively effortful situations over the 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Lifetime (according to DSM 5):
Additional exclusion criteria for a safe application of tVNS:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The cross-over design includes one group which starts with high-intensity stimulation (n = 40) and another group, who starts with low-intensity stimulation (n = 40). The first group receives at first high-intensity for 6 weeks, followed by a low-intensity stimulation phase for 6 weeks. To control for placebo effects, other forty individuals start with the 6-week low-intensity stimulation phase followed by 6 weeks of high-intensity tVNS stimulation phase.
Device: transcutaneous vagus nerve stimulation · Behavioral: Monitoring · Device: cardiowatch bracelet
Another group of patients is included as a control group (n = 40) undergoing 'treatment as usual' for Long/Post Covid. This group of participants receive the same monitoring throughout their participation during 12 weeks as the Stimulation-Group. As there is no standardized treatment protocol for Long/Post Covid, 'treatment as usual' implies a supportive approach. This group of participants have the option to receive taVNS stimulation after participating in the study.
Behavioral: Monitoring · Device: cardiowatch bracelet
The study employs a CE-certified tVNS® E device, ensuring European safety standards (EU regulation 2017/745 on medical devices). This device features a stimulation cycle of 28 seconds on and 32 seconds off, with a 25 Hz impulse frequency. For the high-intensity group, the stimulation intensity will be individually adjusted in the session before starting the high-intensity tVNS stimulation at home. Recommended daily usage is max. 4 hours, after which it automatically shuts off.
Participants are monitored over 12 weeks using a combination of questionnaires and ecological momentary assessment. This approach allows for a comprehensive assessment of the patient's health and well-being.
The study employs the medically certified cardiowatch bracelet from Corsano (CE-MDR medical certification, FDA 510 (k) cleared) for continuous monitoring of vital signals, such as heart rate, heart rate variability, breathing rate, SpO2, physical activity and sleep.
Stimulation-induced changes in invigoration: frequency of button presses during the first seconds of the trial to gain monetary rewards in the Effort Allocation Task.
Changes in invigoration to work for rewards are operationalized as the relative increase in the frequency of button presses on an Xbox controller during the first seconds of the trial in the Effort Allocation Task.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in symptoms of depression
Changes in symptoms of depression are measured via the Montgomery Asberg Depression Scale. The MADRS comprises 10 items rated on a scale from 0 to 6 to compute a sum score with higher scores indicating severe symptoms of depression.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in physical and mental aspects of fatigue
Changes in fatigue are measured by the Chalder Fatigue scale. The CFS comprises 11 questions rated on a 4-point Likert scale to compute a sum score. It will be measured three times six weeks apart.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in heart rate variability
Changes in heart rate variability are measured by a cardiowatch bracelet to evaluate autonomic nervous system activity. It will be measured over three months daily.
Time frame: during 6-week tVNS compared to during 6-week low-intensity stimulation phase
Stimulation-induced changes in physical activity
Changes in physical activity are measured by step count per day, which are recorded by the cardiowatch bracelet. It will be measured over three months daily.
Time frame: during 6-week tVNS compared to during 6-week low-intensity stimulation phase
Stimulation-induced changes in wanting the monetary rewards
Changes in wanting monetary rewards are measured via a visual analogue scale rating after each effortful trial in the Effort Allocation Task. It will be measured three times six weeks apart.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in exertion
Changes in exertion are measured via a visual analogue scale rating after each effortful trial. It will be measured three times six weeks apart.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in the motivation to invest effort: the discounting rate reflecting rewards devalued by effort
Changes in the motivation to invest effort is quantified by estimating the participant-specific discounting factor (k) and the inverse temperature parameter (β), which are derived by fitting the participant's observed choice behavior in the effort discounting task to discounting models. It will be measured at least twice a week over three months.
Time frame: during 6-week tVNS compared to during 6-week low-intensity stimulation phase
Stimulation-induced changes in metabolic and inflammatory markers
Metabolic hormone levels and inflammatory markers are assessed from blood samples. It will be measured three times six weeks apart.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in health-related quality of life
Changes in health-related quality of life are measured by the Short-Form-12 health survey (SF-12), consisting of 12 questions (weighted sum score). It will be measured three times six weeks apart.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in mood and mood response to effort
Changes in positive and negative mood ratings are measured with the questions of the Positive and Negative Affect Schedule (PANAS) questionnaire on visual analog scales (0-100) four times within each experimental session. For each assessment (4x3 time points), all items will be included in the analyses as repeated measures for NA and PA, respectively.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in maintenance:the average relative frequency across the complete trial to gain monetary rewards in the Effort Allocation Task.
Changes in motivation to work for rewards are operationalized as the average relative increase in the frequency of button presses on an Xbox controller across the complete trial in the Effort allocation task.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in heart rate
Changes in heart rate are measured by a cardiowatch bracelet depending on physical activity phases
Time frame: during 6-week tVNS compared to during 6-week low-intensity stimulation phase
Stimulation-induced changes in effort utility
Effort utility will be calculated as the correlation between trial-wise wanting ratings and effort maintenance (i.e., average button press frequency over the trial).
Time frame: Pre-treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
stimulation-induced changes in self-reported depressive symptoms
Changes in self-reported depressive symptoms will be assessed using the Beck Depression Inventory-II (BDI-II). The BDI consists of 20 items and a sum score is calculated across all items.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in HR
HR is measured continuously with the CardioWatch bracelet during the intervention phases between sessions. HR parameters will be calculated for \~1 h time intervals in which participants reported being at rest each day, to compare changes in resting HR.
Time frame: During 6-week tVNS compared to during 6-week low-intensity stimulation phase
Sensor-based data will be included in exploratory analyses.
Changes in sensory-based data are measured by a cardiowatch bracelet
Time frame: during 6-week tVNS compared to during 6-week low-intensity stimulation phase
Changes in Questionnaires
Questionnaires will be included in exploratory analyses and as a confounding variable.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in bodily symptoms
Somatic symptoms across the body are assessed through the Body Sensation task (BST) in which participants have to indicate their physical sensations on a body silhouette.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Stimulation-induced changes in mood and motivation in daily life
Changes in mood, metabolic, and physical states (25 items, Neuser et al. 2023) are continuously assessed using EMA questions before each discounting task on VAS scales (0-100). The main outcomes include mood assessed using mood state: (Happy - Sad)/100 and motivation (single item).
Time frame: during 6-week tVNS compared to during 6-week low-intensity stimulation phase
Stimulation-induced changes in other self-reported symptoms of fatigue and physical complaints
Changes in physical symptoms and complaints are assessed using multiple questionnaires including the Long Covid-Questionnaire (20 items, sum score), the Fatigue severity scale (FSS, 9 items sum score), a visual analog scale for fatigue (1-10), the Post-Exertional Malaise Questionnaire (PEM-DSQ), Composite autonomic symptom Score 31 (COMPASS-31, 31 items, sum-score), Somatic Symptom Disorder-B Criteria Scale (SSD-12 items, sum-score), Patient Health Questionnaire (PHQ-15, 15 items, sum-score), Work-Ability-Index (WAI, 7 items, sum-score), and Perceived Stress Questionnaire (PSQ, 30 items, and index between 0 and 1) in each session.
Time frame: Pre treatment vs. after 6-week tVNS vs. after 6-week low-intensity stimulation phase
Associations of stimulation-induced changes with the amount of stimulation applied
To assess whether tVNS effects depend on the amount of time stimulation was applied by the participants, we will derive the total number of hours that the participants used the stimulation in the two stimulation phases (high- and low-intensity stimulation
Time frame: Time of stimulation (in hours) was measured daily during the 6-week intervention phases between sessions.
Other Stimulation-induced changes in heart rate variability
HRV is measured with the CardioWatch bracelet during the intervention phases between sessions. HRV parameters will be calculated for each hour of each day.
Time frame: Stimulation-induced changes (i.e., high-intensity vs. low-intensity vs. no stimulation) in hourly HRV were assessed daily during the 6-week intervention phases between sessions.
Started Jul 2024 (actual). Primary completion is estimated for May 2027, 34 months after the start.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 34 months is above that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
University Hospital Tuebingen →